mnpr20240502

0001437749-24-015453.txt : 20240509 0001437749-24-015453.hdr.sgml : 20240509 20240509070018 ACCESSION NUMBER: 0001437749-24-015453 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 24928456 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240502_8k.htm FORM 8-K mnpr20240502_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2024

MONOPAR THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39070		32-0463781
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1000 Skokie Blvd., Suite 350, Wilmette, IL		60091
(Address of principal executive offices)		(Zip Code)

(847) 388-0349

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		MNPR		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition

On May 9, 2024, Monopar Therapeutics Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.		Description
99.1		Press Release Dated May 9, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Monopar Therapeutics Inc.

Date: May 9, 2024	By:	/s/ Kim R. Tsuchimoto
	Name:	Kim R. Tsuchimoto
	Title:	Chief Financial Officer and Director

EX-99.1 2 ex_666580.htm EXHIBIT 99.1 ex_666580.htm

Exhibit 99.1

Monopar Therapeutics Reports First Quarter 2024

Financial Results and Strategic Focus on its Radiopharma Pipeline

Initiated MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial

MNPR-101-RIT Phase 1 Clinical Trial Targeted for Launch as Early as Q4 2024 or Q1 2025

Wilmette, IL, May 9, 2024 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical‐-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced first quarter 2024 financial results and summarized recent developments.

Recent Developments

The radiopharma space has had numerous positive recent developments and announcements, from acquisitions to clinical data to reimbursement rates to commercial demand. Since this past December alone, four significant acquisitions have been publicly announced or completed which have had upfront payments ranging from approximately $1 billion to over $4 billion (BMS/RayzeBio, AstraZeneca/Fusion Pharma, Eli Lilly/POINT BioPharma, and Novartis/ Mariana Oncology).

Monopar has been generating promising preclinical data, and recently entered the clinic with its novel, proprietary MNPR-101 radiopharma program targeting the urokinase plasminogen activator receptor (uPAR). Based on these advances, Monopar has made the strategic decision to focus its resources on the assets and capabilities it has been building up in the radiopharma space. As such, the Company is winding down its non-radiopharma programs, including camsirubicin (and its Phase 1b clinical trial) as well as MNPR-202. The Company is targeting launching its second radiopharma clinical trial as early as the end of this year or the first quarter of 2025.

MNPR‐-101 for Radiopharmaceutical Use – First-in-Human Study with MNPR-101-Zr is Now Active

	●	Received clearance and recently initiated a first-in-human Phase 1 imaging and dosimetry clinical trial with novel radiopharmaceutical MNPR-101-Zr in advanced cancer patients. Further information about the MNPR-101-Zr trial is available at www.ClinicalTrials.gov under study identifier NCT06337084. This study is being led by internationally recognized radiopharmaceutical physician Prof. Rodney Hicks, founder of the Melbourne Theranostic Innovation Centre (MTIC).
	●	Optimized imaging and therapeutic MNPR-101 radiopharma programs, significantly increasing tumor uptake while minimizing uptake in healthy tissue (link). This work led to in vivo efficacy studies demonstrating near complete elimination of the tumor after a single injection of the MNPR-101 radiopharmaceutical agent.
	●	Imaged the biodistribution of a therapeutic radioisotope bound to MNPR-101, and demonstrated highly preferential tumor uptake in the tumor consistent with what is seen with the Zr-89 imaging radioisotope (link).
	●	Filed a provisional patent application to protect the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharma programs.
	●	Announced that Monopar’s abstract on MNPR-101-Zr radiopharma program was selected for presentation at the Society of Nuclear Medicine and Molecular Imaging’s Annual Meeting on June 8-11, 2024.
	●	Monopar is targeting initiating a Phase 1 clinical study in advanced cancers with its therapeutic radiopharmaceutical MNPR-101-RIT as soon as the end of this year or early next year.

Results for the First Quarter Ended March 31, 2024, Compared to the First Quarter Ended March 31, 2023

Cash and Net Loss

Cash, cash equivalents and short-term investments as of March 31, 2024, were $8.8 million. Monopar projects that its current funds will be sufficient to continue operations at least through June 30, 2025, to continue to conduct and conclude its first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr, and to advance the preclinical MNPR-101-RIT therapeutic program into the clinic. Monopar will require additional funding to advance its preclinical and clinical programs beyond that, and anticipates seeking to raise additional capital within the next 12 months to fund its future operations.

Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.

Research and Development (R&D) Expenses

R&D expenses for the first quarter of 2024 were $966,000 compared to $1,653,000 for the first quarter of 2023. This decrease of $687,000 was primarily due to a decrease of $716,000 in Validive clinical trial-related expenses due to the closure of the trial in March 2023, partially offset by a net increase of $29,000 in other R&D expenses.

General and Administrative (G&A) Expenses

G&A expenses for the first quarter of 2024 were $757,000, compared to $872,000 for the first quarter of 2023. This represents a decrease of $115,000 primarily attributed to (1) a decrease in stock-based compensation to the non-employee directors of $70,000 as no equity awards were issued in the first quarter of 2024 compared to the first quarter of 2023, (2) a reduction of $62,000 in patent expenses related to the closure of the Validive trial, and (3) a reduction of stock-based compensation expenses to employees of $16,000 due to the full vesting of the 2020 grants in the fourth quarter of 2023, partially offset by a net increase in consulting, tax services and other G&A expenses of $33,000.

About Monopar Therapeutics

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers. For more information, and links to SEC filings that contain detailed financial information, visit: https://ir.monopartx.com/quarterly-reports.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include and are not limited to: that Monopar is targeting initiating a Phase 1 clinical study in advanced cancers with its therapeutic radiopharmaceutical MNPR-101-RIT as soon as the end of this year or early next year; and that current funds will be sufficient for Monopar to continue operations at least through June 30, 2025, to continue to conduct and conclude its first-in-human clinical trial with Monopar’s MNPR-101-Zr radiopharmaceutical program, and to advance the preclinical MNPR-101-RIT therapeutic program into the clinic. The forward-looking statements involve risks and uncertainties including, but not limited to: that we may expend available funds sooner than anticipated or require additional funding due to change in circumstances or unanticipated events; that future preclinical or clinical data will not be as promising as the data to date; not enrolling sufficient patients in the MNPR-101-Zr Phase 1 clinical trial or at all; that MNPR-101-Zr and/or MNPR-101 conjugated to a therapeutic radioisotope may cause unexpected serious adverse effects or fail to image or be effective against the cancer tumors in humans; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

EX-101.SCH 3 mnpr-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 mnpr-20240509_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 mnpr-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Entity, Ex Transition Period Amendment Flag Entity, Central Index Key EX-101.PRE 6 mnpr-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 monologo.jpg begin 644 monologo.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	May 09, 2024
Document Information [Line Items]
Entity, Registrant Name	MONOPAR THERAPEUTICS INC.
Document, Type	8-K
Document, Period End Date	May 09, 2024
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-39070
Entity, Tax Identification Number	32-0463781
Entity, Address, Address Line One	1000 Skokie Blvd., Suite 350
Entity, Address, City or Town	Wilmette
Entity, Address, State or Province	IL
Entity, Address, Postal Zip Code	60091
City Area Code	847
Local Phone Number	388-0349
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	MNPR
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	true
Entity, Ex Transition Period	true
Amendment Flag	false
Entity, Central Index Key	0001645469

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.mnpr.com/20240509/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports mnpr-20240509.xsd mnpr-20240509_def.xml mnpr-20240509_lab.xml mnpr-20240509_pre.xml mnpr20240502_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mnpr20240502_8k.htm": { "nsprefix": "mnpr", "nsuri": "http://www.mnpr.com/20240509", "dts": { "schema": { "local": [ "mnpr-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "mnpr-20240509_def.xml" ] }, "labelLink": { "local": [ "mnpr-20240509_lab.xml" ] }, "presentationLink": { "local": [ "mnpr-20240509_pre.xml" ] }, "inline": { "local": [ "mnpr20240502_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.mnpr.com/20240509/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "mnpr20240502_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "mnpr20240502_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.mnpr.com/20240509/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001437749-24-015453-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-015453-xbrl.zip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end XML 19 mnpr20240502_8k_htm.xml IDEA: XBRL DOCUMENT 0001645469 2024-05-09 2024-05-09 false 0001645469 8-K 2024-05-09 MONOPAR THERAPEUTICS INC. DE 001-39070 32-0463781 1000 Skokie Blvd., Suite 350 Wilmette IL 60091 847 388-0349 Common Stock, $0.001 par value MNPR NASDAQ false false false false true true